Organization (Hospital)
Azienda Ospedaliera Cardinale G. Panico
ClinicalTrials.gov lists Azienda Ospedaliera Cardinale G. Panico as lead sponsor of 13 trials. It has 1 active development program and 1 approved asset.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 0 registered with a 2026 start date. The dashed outline is the pace from the 0 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 0.2 trial starts a year over the five years to September, under the 5 a year the method needs.
This page covers Azienda Ospedaliera Cardinale G. Panico: 13 lead-sponsored trials and 0 legal-entity registrations.
Disease areas (12)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Consciousness Disorders | 3 |
| Pelvic Organ Prolapse | 3 |
| Syncope | 3 |
| Atrial Fibrillation | 2 |
| Bradycardia | 2 |
Showing 5 of 12 disease areas.
Trials by start year as sponsor or collaborator (8)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2022 | 1 |
| 2019 | 2 |
| 2018 | 1 |
| 2016 | 3 |
| 2015 | 3 |
| 2013 | 1 |
| 2011 | 1 |
| 2010 | 2 |
Recruitment duration, a model prediction: none of the 13 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (1)
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| Pacemaker and defibrillator | Bradycardia | Not reported | 1 |
Approved assets (1)
| Drug | Trials |
|---|---|
| ROTIGOTINE | 1 |
Journals published in (5)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Heart rhythm | 3 |
| Archives of gynecology and obstetrics | 1 |
| Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology | 1 |
| European journal of cardiovascular nursing | 1 |
| The New England journal of medicine | 1 |
Latest dated events (14)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2022-09-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2019-11-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2019-09-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2018-08-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2016-11 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
Showing 5 of 14 events.
Biomarkers this organization publishes on (1)
| Biomarker | Publications |
|---|---|
| KRT20 | 1 |
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, sponsor delivery record, us granted patents, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, organization relationships, clia clinical laboratory certificates, and biomarker capability evidence.